Evidence check: AMH in the context of Wechseljahre

AMH (anti-Müllerian hormone) is often marketed as a marker of ovarian reserve in the context of menopause. Evidence shows that while AMH correlates with the number of remaining eggs, it is not a reliable predictor of menopause timing. Individual variability is high, and levels fluctuate with cycle phase, age, and laboratory methods. Studies indicate a moderate association between low AMH and earlier menopause, but predictive accuracy is insufficient for clinical decision-making. Consumer tests offering AMH as a standalone menopause marker often overstate its utility. The German Society for Gynecology and Endocrinology does not recommend AMH for routine menopause diagnosis. Additionally, standardized reference ranges across age groups are lacking. A single AMH measurement without other hormonal parameters (FSH, estradiol) and clinical symptoms is not meaningful. Caution is warranted when interpreting results from direct-to-consumer tests, as they may not come from certified laboratories. In summary, AMH provides clues but no definitive answer regarding menopause onset.